PYC Therapeutics Limited

PYC

PYC Therapeutics Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The firm utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The firm's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.

Droneshield Limited

DRO

DroneShield Ltd. engages in the development and commercialisation of hardware and software technology for drone detection and security. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-06-22. The company provides artificial intelligence-based platforms for protection against advanced threats, such as drones and autonomous systems. The company offers customers bespoke counter-drone (or counter-UAS) and electronic warfare solutions and off-the-shelf products designed to suit a variety of terrestrial, maritime, or airborne platforms. The Company’s products include DroneGun Tactical, DroneGun MKIII, DroneSentry, DroneSentry-C2, DroneSentry-X, RfPatrol and DroneSim among others. The DroneGun Tactical is an unmanned aerial systems (UAS) countermeasure designed for two-hand operation and long-range defeat. RfPatrol is a passive/non-emitting wearable UAS detection device. The Company’s capabilities include C-UAS, C-UxS Training, and Electronic Warfare.

Vanguard Diversified High Growth Funds

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

NASDAQ US 100

NDQ

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.